Ratings by Roth/MKM (Jerry Issacson)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/19/2019 | Altimmune | ALT | New Coverage | Buy (N/A) |
2.45 (1.76) |
-28.16% | Details | |
| 5/24/2019 | Stemline Therapeutics | STML | New Coverage | Buy (N/A) |
15.13 (11.83) |
-21.81% | Details | |
| 5/24/2019 | Cyclacel Pharmaceuticals | CYCC | New Coverage | Buy (N/A) |
0.65 (4.02) |
518.46% | Details | |
| 5/24/2019 | Aptevo Therapeutics | APVO | New Coverage | Buy (N/A) |
0.74 (0.39) |
-47.3% | Details | |
| 5/24/2019 | Moleculin Biotech | MBRX | New Coverage | Buy (N/A) |
1.15 (4.31) |
274.78% | Details | |
| 4/30/2019 | Zynerba Pharmaceuticals | ZYNE | New Coverage | Buy (N/A) |
10.99 (5.64) |
-48.68% | Details | |
| 2/11/2019 | Matinas BioPharma Holdings Inc. | MTNB | New Coverage | Buy (N/A) |
1.07 (0.18) |
-83.18% | Details | |
| 12/6/2018 | CorMedix | CRMD | New Coverage | Buy (N/A) |
1.35 (5.19) |
284.44% | Details |
